Literature DB >> 20466619

Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment.

Francesc Casas1, Josep María Borràs, Ferran Ferrer, Núria Guanyabens, Rafael Gutiérrez del Pozo, Concha León, José López Torrecilla, Begoña Mellado, Joan Morote, Manel Puig, María José Ribal, Carme Ruscalleda, Agustí Serra, Valentí Valls, Almudena Zapatero.   

Abstract

INTRODUCTION: Prostate cancer (PC) is one of the tumours with the highest incidence in recent years. PC therapies have several adverse effects. A panel consensus recommendation has been made to prevent or ameliorate complications in PC treatment to improve quality of life.
MATERIAL AND METHODS: Fifteen specialists have met to analyse the different toxicities associated with PC treatment. Each medical specialist performed a National Library of Medicine PubMed search citations searching about these secondary effects and his specialty from 1999 to 2009 to propose measures for their prevention/amelioration.
RESULTS: Surgery is associated with incontinence and impotence. Radiotherapy can produce acute, late urological and gastrointestinal toxicity. Brachytherapy can produce acute urinary retention. Chemotherapy is associated with haematotoxicity, peripheral neuropathy and diarrhoea, and hormone therapy can produce osteoporosis, metabolic syndrome, cognitive and muscular alterations, cardiotoxicity, etc.
CONCLUSIONS: Improvement in surgical techniques and technology (IMRT/IGRT) can prevent surgical and radiotherapeutic toxicity, respectively. Brachytherapy toxicity can be prevented with precise techniques to preserve the urethra. Chemotherapy toxicity can be prevented with personalized schedules of treatment and close follow-up of iatrogenia and hormone therapy toxicity can be prevented with close follow-up of possible secondary effects.

Entities:  

Mesh:

Year:  2010        PMID: 20466619     DOI: 10.1007/s12094-010-0516-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  97 in total

1.  Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.

Authors:  Howard Huaihan Pai; Charles Ludgate; Tom Pickles; Chuck Paltiel; Alex Agranovich; Eric Berthelet; Graeme Duncan; Charmaine Kim-Sing; Winkle Kwan; Jan Lim; Mitchell Liu; Scott Tyldesley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

2.  Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.

Authors:  Sarah Gutman; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Zachariah Allen; Robert W Galbreath; Edward Adamovich
Journal:  BJU Int       Date:  2006-01       Impact factor: 5.588

3.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

4.  A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding.

Authors:  Frank J Penedo; Ivan Molton; Jason R Dahn; Biing-Jiun Shen; Dave Kinsinger; Lara Traeger; Scott Siegel; Neil Schneiderman; Michael Antoni
Journal:  Ann Behav Med       Date:  2006-06

5.  Rectal complications after prostate brachytherapy.

Authors:  Shimul A Shah; Robert R Cima; Eric Benoit; Elizabeth L Breen; Ronald Bleday
Journal:  Dis Colon Rectum       Date:  2004-08-12       Impact factor: 4.585

6.  Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.

Authors:  Almudena Zapatero; Feliciano García-Vicente; Ignasi Modolell; Pino Alcántara; Alejandro Floriano; Alfonso Cruz-Conde; Juan J Torres; Armando Pérez-Torrubia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

Review 7.  Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.

Authors:  Celestia S Higano
Journal:  Urol Oncol       Date:  2003 Sep-Oct       Impact factor: 3.498

Review 8.  Androgens and cardiovascular disease.

Authors:  Peter Y Liu; Alison K Death; David J Handelsman
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

View more
  2 in total

1.  Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.

Authors:  Janet Harden; Martin G Sanda; John Thomas Wei; Hossein N Yarandi; Larry Hembroff; Jill Hardy; Laurel Northouse
Journal:  Oncol Nurs Forum       Date:  2013-11       Impact factor: 2.172

2.  A study of segment weight optimization with the CMS XiO step-and-shoot IMRT technique for prostate cancer.

Authors:  Ramachandran Prabhakar; Jim Cramb; Christopher Gehrke; Justin Anderson; Judy Andrews
Journal:  J Appl Clin Med Phys       Date:  2012-01-05       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.